MX2022014225A - Metodos para tratar cancer utilizando una combinacion de conjugados de farmaco-anticuerpo anti-cd30. - Google Patents

Metodos para tratar cancer utilizando una combinacion de conjugados de farmaco-anticuerpo anti-cd30.

Info

Publication number
MX2022014225A
MX2022014225A MX2022014225A MX2022014225A MX2022014225A MX 2022014225 A MX2022014225 A MX 2022014225A MX 2022014225 A MX2022014225 A MX 2022014225A MX 2022014225 A MX2022014225 A MX 2022014225A MX 2022014225 A MX2022014225 A MX 2022014225A
Authority
MX
Mexico
Prior art keywords
antibody
combination
drug conjugates
methods
treating cancer
Prior art date
Application number
MX2022014225A
Other languages
English (en)
Inventor
Maureen Ryan
Jessica Kelly Simmons
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2022014225A publication Critical patent/MX2022014225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención proporciona una combinación de dos conjugados de fármaco-anticuerpo anti-CD30, tal como brentuximab vedotin y SGN-CD30C, para el tratamiento de cáncer, tal como el cáncer hematológico. La invención también proporciona composiciones farmacéuticas y kits que comprenden una combinación de dos conjugados de fármaco-anticuerpo anti-CD30, tal como brentuximab vedotina y SGN-CD30C, para su uso en el tratamiento de cáncer.
MX2022014225A 2020-05-13 2021-05-12 Metodos para tratar cancer utilizando una combinacion de conjugados de farmaco-anticuerpo anti-cd30. MX2022014225A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063024279P 2020-05-13 2020-05-13
PCT/US2021/031985 WO2021231568A1 (en) 2020-05-13 2021-05-12 Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates

Publications (1)

Publication Number Publication Date
MX2022014225A true MX2022014225A (es) 2023-02-09

Family

ID=76284179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014225A MX2022014225A (es) 2020-05-13 2021-05-12 Metodos para tratar cancer utilizando una combinacion de conjugados de farmaco-anticuerpo anti-cd30.

Country Status (10)

Country Link
US (1) US20230190949A1 (es)
EP (1) EP4149559A1 (es)
JP (1) JP2023526236A (es)
KR (1) KR20230023650A (es)
CN (1) CN116390770A (es)
AU (1) AU2021273256A1 (es)
CA (1) CA3183602A1 (es)
IL (1) IL298155A (es)
MX (1) MX2022014225A (es)
WO (1) WO2021231568A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5573920A (en) 1991-04-26 1996-11-12 Surface Active Limited Antibodies, and methods for their use
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
CA3051090C (en) 2009-01-09 2022-04-12 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR102645430B1 (ko) * 2013-10-15 2024-03-11 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
JP2019517505A (ja) * 2016-06-02 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ−１抗体の使用
JP7244987B2 (ja) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
JP2020536932A (ja) * 2017-10-13 2020-12-17 シアトル ジェネティクス インコーポレーテッド 抗体−薬物コンジュゲートを用いた免疫応答の調節
IL277748B1 (en) 2018-04-06 2024-03-01 Seagen Inc Camptothecin peptide conjugates
TW202015740A (zh) * 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
WO2020072519A1 (en) * 2018-10-01 2020-04-09 Seattle Genetics, Inc. Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
CA3152316A1 (en) * 2019-10-04 2021-04-08 Scott C. Jeffrey Camptothecin peptide conjugates
WO2021067820A1 (en) * 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate

Also Published As

Publication number Publication date
CA3183602A1 (en) 2021-11-18
EP4149559A1 (en) 2023-03-22
WO2021231568A1 (en) 2021-11-18
IL298155A (en) 2023-01-01
US20230190949A1 (en) 2023-06-22
KR20230023650A (ko) 2023-02-17
CN116390770A (zh) 2023-07-04
AU2021273256A1 (en) 2022-12-15
JP2023526236A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
LUC00011I2 (es)
TW200515910A (en) Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibitor of cancer
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie
MX2020009111A (es) Metodos para tratar cancer con una combinacion de un agente basado en platino y un conjugado de anticuerpo anti-factor tisular-farmaco.
EP4295917A3 (en) Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
MX2022014225A (es) Metodos para tratar cancer utilizando una combinacion de conjugados de farmaco-anticuerpo anti-cd30.
MX2023008327A (es) Anticuerpos inmunomoduladores de anticuerpo-farmaco.
CA3156022A1 (en) METHODS OF TREATING CANCER USING A COMBINATION OF A PLATINUM AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
MX2022009389A (es) Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de linfoma no hodgkin.
MX2022005240A (es) Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih.
MX2023005156A (es) Composiciones terapeuticas sensibles al ph.
MX2022015375A (es) Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
MX2022009696A (es) Combinacion que contiene un conjugado de anticuerpo-farmaco que comprende derivado de duocarmicina y tiosulfato.